The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide

Dr. Carel le Roux delivers an expert overview of the highly anticipated findings from the SYNCHRONIZE™ Phase 3 clinical studies, presented at the ADA Scientific Sessions. The discussion focuses on the clinical benefits of glucagon/GLP-1 receptor dual agonism, showcasing new data on survodutide. This recap highlights how targeting both pathways offers a powerful approach to weight management and metabolic health, marking a significant step forward in obesity care.Video: https://medicaldigest.org/scientific-contents/interview:benefits-glucagonglp-1-receptor-dual-agonism-insights-synchronize-phase-3-studies-survodutide